APA (7th ed.) Citation

H, B., S, G., EE, V., LQM, C., MA, B., J, d. C. C., . . . J, B. (2021). Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(7), 723. https://doi.org/10.1200/JCO.20.01605

Chicago Style (17th ed.) Citation

H, Borghaei, et al. "Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 39, no. 7 (2021): 723. https://doi.org/10.1200/JCO.20.01605.

MLA (9th ed.) Citation

H, Borghaei, et al. "Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 39, no. 7, 2021, p. 723, https://doi.org/10.1200/JCO.20.01605.